(UroToday.com) In a plenary presentation in the Progress and Promise in Treatment Personalization for Advanced Prostate Cancer session at the 2021 ASCO GU Cancers Symposium, Dr. Peter Nelson discussed the role of PARP inhibitors in prostate cancer, highlighting the PARP inhibitor trials, the mechanisms informing biomarkers, questions of precision and accuracy, issues with assay, and potential further opportunities and next steps.